nanotech investing Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
nanotech investing Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
nanotech investing Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
nanotech investing Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
nanotech investing Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
nanotech investing Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
nanotech investing Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
nanotech investing Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
nanotech investing Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
nanotech investing Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
nanotech investing Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
nanotech investing Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
nanotech investing Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
nanotech investing Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
Steadright Critical Minerals Inc. to Acquire up to 75% Interest in the Péribonka Ree-Niobium Carbonatite Project, Saguenay-Lac-St-Jean Region, Québec
Prismo Metals Announces Listing of Blade Resources on the CSE Prismo Metals Owns 6,755,000 Shares of Blade Resources
Goldgroup Highlights Its Two Producing Mines and Significant Growth Potential Across the Don David Gold Complex in Mexico
